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Abstract
BRCA2 (also known as FANCD1) is a core component of the Fanconi pathway and sup-
presses transformation of immature T-cells in mice. However, the contribution of Fanconi-
BRCA pathway deficiency to human T-cell acute lymphoblastic leukemia (T-ALL) remains
undefined. We identified point mutations in 9 (23%) of 40 human T-ALL cases analyzed,
with variant allele fractions consistent with heterozygous mutations early in tumor evolution.
Two of these mutations were present in remission bone marrow specimens, suggesting
germline alterations. BRCA2 was the most commonly mutated gene. The identified Fan-
coni-BRCA mutations encode hypomorphic or null alleles, as evidenced by their inability to
fully rescue Fanconi-deficient cells from chromosome breakage, cytotoxicity and/or G2/M
arrest upon treatment with DNA cross-linking agents. Disabling the tumor suppressor activ-
ity of the Fanconi-BRCA pathway is generally thought to require biallelic gene mutations.
However, all mutations identified were monoallelic, and most cases appeared to retain
expression of the wild-type allele. Using isogenic T-ALL cells, we found that BRCA2 haploin-
sufficiency induces selective hypersensitivity to ATR inhibition, in vitro and in vivo. These
findings implicate Fanconi-BRCA pathway haploinsufficiency in the molecular pathogenesis
of T-ALL, and provide a therapeutic rationale for inhibition of ATR or other druggable effec-
tors of homologous recombination.
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Introduction
The Fanconi pathway functions in the repair of DNA inter-strand crosslinks and stalled repli-
cation forks [1]. Stalled replication forks trigger activation of the upstream Fanconi complex
(or Fanconi complex 1), which ubiquitinates FANCD2. FANCD2 ubiquitination promotes the
formation of the downstream Fanconi complex (complex 2), which mediates subsequent DNA
repair. Biallelic germline mutations of any Fanconi genes including BRCA2 cause Fanconi ane-
mia, a syndrome characterized by developmental anomalies, bone marrow failure, and a pre-
disposition to acute myeloid leukemia and squamous cell carcinomas [1].
The study of rare genetic cancer predisposition syndromes has revealed fundamental
insights into the pathobiology of sporadic oncogenesis in the general population. For example,
familial adenomatous polyposis, a clinical syndrome associated with highly penetrant colorec-
tal adenocarcinomas [2], is caused by germline mutations of APC [3–5]. Although familial
adenomatous polyposis accounts for only a small fraction of colorectal cancers in the general
population, APC gene mutations are the most common genetic alteration in sporadic colorec-
tal adenocarcinomas [3, 6]. Likewise, germline monoallelic mutations of BRCA1 and BRCA2
cause familial breast and ovarian cancer predisposition syndromes [7, 8], and these genes are
recurrently mutated in sporadic breast and ovarian cancers [9, 10]. While germline or somatic
mutations of these and other Fanconi genes, including upstream Fanconi genes such as
FANCM, have been linked to several tumor types, these are most often carcinomas [9–15].
Given that the pathobiology of sporadic cancers is shared with that of genetic cancer predispo-
sition syndromes across numerous tumor types, the paucity of Fanconi-BRCA mutations
reported in sporadic human leukemias would appear to be discordant with the high incidence
of leukemia in patients with Fanconi anemia [16].
Brca2-deficient mice spontaneously develop T-lymphoblastic malignancies at high fre-
quency [17, 18], and these tumors also occur in Fancc-deficient mice [19]. Furthermore, sev-
eral case reports have described T-lymphoblastic malignancies in individuals with germline
mutations of the Fanconi-BRCA pathway [20–24]. However, the degree to which this pathway
plays a role in human T-cell leukemogenesis remains unclear. Here, we report a high fre-
quency of loss-of-function mutations of Fanconi-BRCA pathway genes in childhood T-ALL.
All mutations identified were monoallelic, and most of these cases retained expression of the
wild-type allele, suggesting partial rather than complete Fanconi-BRCA pathway inactivation.
Despite the clinical benefit of PARP inhibitors in tumors with complete Fanconi-BRCA path-
way inactivation [25, 26], this approach appears to have little efficacy against tumors with
monoallelic BRCA gene mutations [27]. However, we found that BRCA2 haploinsufficient
cells are hypersensitive to ATR inhibition, in vitro and in vivo. Thus, BRCA haploinsufficiency
may represent a targetable pathogenic alteration in T-ALL.
Materials and methods
Patient samples
The primary cohort of T-ALL diagnostic samples consisted of 40 specimens collected from
children with newly diagnosed T-ALL who were enrolled on Dana-Farber Cancer Institute
Study 05–001 between April 2005 and February 2010 (https://clinicaltrials.gov/ct2/show/
NCT00400946), or Children’s Oncology Group Study AALL0434 between January 2007 and
June 2014 (https://clinicaltrials.gov/ct2/show/NCT00408005). The validation cohort consistent
of a distinct 69 pediatric T-ALL patient samples collected from children on Dana-Farber Can-
cer Institute Study 05–001 over the same time period. All samples were obtained prior to the
initiation of chemotherapy. Samples were purified using Ficoll-Paque reagent, and cells were
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viably frozen. All samples were collected with written informed consent and Institutional
Review Board (IRB) approval of the respective institutions, in accordance with the Declaration
of Helsinki.
Targeted exon sequencing of T-ALL patient samples
Targeted exon sequencing for all protein-coding exons of the genes listed in S1 Table was per-
formed using the customized Dana-Farber OncoPanel massively parallel sequencing assay as
described [28]. Briefly, DNA was isolated using the AllPrep DNA/RNA Mini Kit (OPv1
cohort, Qiagen, Venlo, The Netherlands) or the DNeasy kit (OPv3mod cohort; Qiagen)
according to manufracturer’s instructions and DNA concentration analyzed using PicoGreen.
DNA library preparation and hybrid capture were performed as described [28], and samples
were sequenced on an Illumina HISeq 2500. Pooled sample reads were de-convoluted and
sorted using Picard tools (https://github.com/broadinstitute/picard), and aligned to the
human genome using build 37 edition from the Human Genome Reference Consortium, as
described [28]. Mutation analysis for single nucleotide variants (SNV sheet in S3 Table) was
performed using MuTect v1.1.4. Analysis for insertions/deletions (INDEL sheet in S3 Table)
was performed using the SomaticIndelDetector tool. Analysis for multiple CNVs in the same
codon was performed using the GATK ReadBackPhasing Tool (PHASED sheet in S3 Table),
as described [29]. The Best Effect single nucleotide variant (SNV) and indel data were then
filtered using the 6,500 exome release of the Exome Sequencing Project (ESP) database and
queried against dbSNP and COSMIC database. Fanconi-BRCA pathway genes sequenced
included FANCA, FANCC, FANCE, FANCF and FANCG, BRCA2/FANCD1, FANCD2,
BRIP1/FANCJ, PALB2/FANCN, and ERCC4/FANCQ. BRCA1, which has recently been
shown to also be a Fanconi gene [30], was also sequenced.
Mutation calls were made for mutations with an allele fraction� 0.3, and the mutation
was predicted to result in a non-synonymous amino acid alteration, or predicted to disrupt
a start codon, stop codon, or splice site. Mutations were excluded if they were present at
any frequency in dbSNP or in the Exome Variant Server, NHLBI GO Exome Sequencing
(http://evs.gs.washington.edu/EVS/) at the time of analysis. Data from targeted exon sequenc-
ing and RNA sequencing of primary T-ALL patient samples is available in the dbGap con-
trolled-access database (https://www.ncbi.nlm.nih.gov/gap), study ID: phs001513, which
is accessible to users with the appropriate institutional certifications for human subject
projections.
Array CGH analysis of T-ALL patient samples
All samples analyzed by targeted exon sequencing in the primary cohort that had sufficient
material available (n = 36 of 40 in OPv1 cohort) were also profiled for DNA copy number
analysis using SurePrint G3 Human 4×180K CGH Microarrays (Agilent Technologies, Santa
Clara, CA). Patient and control genomic DNAs (gDNAs) were labeled with Cy3 and Cy5 dyes
(PerkinElmer, Waltham, MA) and hybridization was performed according to the manufac-
turer’s instructions (Agilent Technologies), followed by data-analysis using the arrayCGH-
base tool [31]. Segmentation was performed with the BioConductor DNAcopy package
(http://www.bioconductor.org/packages/2.2/bioc/html/DNAcopy.html), as previously
described [32]. Log2 copy number ratio for heterozygous deletion was defined as -0.5 to -1.5
(corresponding to 35–70% of normal copy number), and log2 copy number ratio for homozy-
gous deletion was defined as less than -1.5 (corresponding to <35% of normal copy number).
Log2 copy number ratio for duplication was 0.32 to 0.81 (corresponding to 25 to 75% of
normal copy number), and Log2 copy number ratios greater than 0.81 were considered
Fanconi-BRCA mutations in T-ALL
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amplification. Array CGH data are available in the NCBI Gene Expression Omnibus (https://
www.ncbi.nlm.nih.gov/geo/) as GSE96624.
Sanger sequencing
For Sanger sequencing of genomic DNA, PCR amplification of the region of interest sur-
rounding each mutation was performed using the OneTaq Hot Start kit (Qiagen, Hilden, Ger-
many) with the forward (F) and reverse (R) primers listed in S6 Table. PCR products were
then purified using the QIAquick PCR purification kit (Qiagen) and sent for sequencing with
the sequencing primers listed at S6 Table.
For sequencing of the cDNA, RNA was isolated from the samples using the AllPrep Kit
(Qiagen) as above, treated with DNase I (Thermo Fisher, Waltham, MA), and then used for
cDNA synthesis using the SuperScript III First-Strand Synthesis System (Thermo Fisher). The
cDNA product was then used for PCR amplification with the primers listed in S6 Table using
the OneTaq Hot Start kit (Qiagen). The PCR product was purified using QIAquick PCR puri-
fication kit (Qiagen) and sent for sequencing. Sanger sequencing was performed by Genewiz
(South Plainfield, NJ).
Patient derived xenografts
Viable T-ALL blasts collected from children with T-ALL were engrafted and expanded in
immunodeficient mice, as described [33]. Cells were cultured in alpha-minimum essential
media supplemented with 10% FBS, 10% human AB serum (Invitrogen), 1% L-glutamine, 1%
penicillin/streptomycin in the presence of recombinant human cytokines stem cell factor (50
ng/ml), Flt3-L (20 ng/ml) and interleukin-7 (10 ng/ml; R&D Systems, Minneapolis, MN, USA)
at 37 ˚C under 5% CO2. All mouse experiments were approved by the Boston Children’s Hos-
pital Institutional Animal Care and Use Committee, and performed in accordance with all
regulations.
Fanconi deficient cell lines
The following Fanconi deficient cell lines were used: VU423 (also known as EUFA423) cells,
which harbor compound heterozygous BRCA2 inactivating mutations [34]; PD20 cells, which
harbor compound heterozygous FANCD2 inactivating mutations [35]; GM6914 cells, which
are FANCA deficient [36]; PD331 cells, which are FANCC deficient [37]; EUFA121.L cells,
which have compound heterozygous inactivating mutations of FANCF [38]; and HSC 563.L
cells, which are deficient for FANCE. All cell lines were obtained from the Alan D’Andrea lab-
oratory or the Oregon Health Sciences University Fanconi Anemia Cell Repository (http://
www.ohsu.edu/research/fanconi-anemia/celllines.cfm). EUFA 121.L cells were cultured in
RPMI with 15% FBS with 1% penicillin and streptomycin (P/S). VU423, GM6914, PD20 and
PD331 cells were cultured in DMEM with 10% FBS with 1% P/S.
Fanconi expression constructs and site-directed mutagenesis
A pcDNA3 plasmid was used to drive expression of wild-type BRCA2 and G418 resistance. A
PMMP retroviral vector was used to drive expression of FANCD2, FANCA, FANCC, or
FANCF and puromycin resistance. Site-directed mutagenesis was performed on the wild-type
plasmids to generate expression constructs encoding each of the T-ALL-associated mutations
shown, using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA) and the primers in S6 Table. All plasmids were Sanger sequenced to confirm
correct introduction of the patient-derived mutations.
Fanconi-BRCA mutations in T-ALL
PLOS ONE | https://doi.org/10.1371/journal.pone.0221288 November 13, 2019 4 / 22
Lentiviral and retroviral production and transduction of cell lines
Viral particles for PMMP-driven expression constructs for FANCD2, FANCA, FANCC, or
FANCF were generated by co-transfecting these plasmids into HEK 293T cells together with
packaging plasmids pMD and p-CMV-VSV-G using Fugene 6 (Promega, Madison, WI). Len-
tiviruses were generated by co-transfecting pLenti CMV Puro DEST plasmid with packaging
vectors psPAX2 (https://www.addgene.org/12260/) and pMD2.G (https://www.addgene.org/
12259/) using Fugene (Promega, Madison, WI). The appropriate Fanconi-deficient cell lines
were infected with each of the wild-type and point mutant constructs for that gene by incubat-
ing cells for 24 hours in virus-containing supernatant in the presence of polybrene at 8 μg/mL.
Controls were pcDNA3-Luciferase (control for BRCA2), or PMMP empty vector (FANCD2,
FANCA, FANCC, FANCF). Selection was with G418 (BRCA2) or puromycin (FANCD2,
FANCA, FANCC, FANCF) at 2 μg/ml beginning 48 hours after infection for at least 72 hours.
The BRCA2 coding sequence is too large for standard viral packaging, so cells were trans-
fected with pcDNA3 constructs encoding wild-type or mutant BRCA2, or Luciferase control,
using Lipofectamine 2000 (Thermo Fisher Scientific). Selection for successfully transfected
cells was with G418 treatment at 500 μg/ml beginning 48 hours after transfection and continu-
ing for a minimum of 10 days.
Quantitative Reverse Transcriptase PCR and primers
RNA was isolated from cells transduced with the indicated constructs using the RNeasy kit
(Qiagen), and cDNA was synthesized using the SuperScript III First-Strand Synthesis System
using the oligo(dT)20 primers provided (Thermo Fisher Scientific). Q-RT-PCR was performed
using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) and a 7500 Real-Time
PCR system (Applied Biosystems) using the primers for each target gene in listed in S6 Table.
Beta-actin was the control, and relative gene expression was calculated using the ΔΔCt
method.
Western Blotting
Cells were lysed with 10 mM HEPES pH 8.0, 8 M Urea, 1% CHAPS, 150 mM NaCl, 1 mM
EDTA, 10 mM glycine supplemented with protease cocktail inhibitor (Roche), resolved by
NuPAGE (Invitrogen) gels (NuPAGE 4–12% Bis-Tris for FANCA, FANCC, FANCD2 and
FANCF and NuPAGE Tris-Acetate 3–8% for BRCA2) and transferred onto nitrocellulose
membrane. The following antibodies were used, FANCA (Bethyl Labs), FANCC (ID#3831,
OHSU, Fanconi Anemia Antibody Project, Portland, OR, USA), BRCA2/FANCD1-1 (D0405,
OHSU, Fanconi Anemia Antibody Project, Portland, OR, USA), FANCD2 (SC-20022, Santa
Cruz, Dallas, TX, USA) FANCF (ab47624m, Abcam, Cambridge, MA, USA), beta-Actin (Cell
Signaling Technologies, Danvers, MA, USA). Secondary antibodies were anti-mouse IgG,
HRP-linked Antibody and anti-rabbit IgG, HRP-linked antibody (Cell Signaling Technologies,
Danvers, MA, USA). Detection was with Supersignal™ West Pico PLUS chemiluminescent
Substrate (Thermo Scientific, Waltham, MA,USA) using the Amersham Imager 600 (GE
Healthcare Life Sciences).
Mitomycin C complementation assays
Mitomycin C was obtained from Sigma-Aldrich (St. Louis, MO) and dissolved in water. For
chromosomal breakage assays, cells were plated at 5 million cells/10 ml of media. Cells were
treated with mitomycin C (20 ng/ml) or vehicle control (water) for 48 hours at 37˚C with 5%
CO2, at which time colcemid was added to final concentration of 100 ng/mL for 1 hour.
Fanconi-BRCA mutations in T-ALL
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Adherent cells were trypsinized and incubated in 10 ml hypotonic 0.075 M KCl for 20 minutes.
Two ml of methanol:acetic acid (3:1) was added to each sample, samples were centrifuged at
500 g x 10 minutes, and supernatant was removed. Cells were then resuspended in 5 mL of
methanol:acetic acid fix (3:1), centrifuged at 500 g x 10 minutes, a procedure that was repeated
a total of 3 times after removing the supernatant. Cells were then dropped onto microscope
slides and stained with Wright’s stain, after which 25 metaphase spreads from each of a mini-
mum of 3 different slides was analyzed for each sample. Microscopy was performed using an
100x objective on an Axio Imager A1 microscope (Zeiss, Oberkochen, Germany), with images
captured using a CV-A10 digital camera (Jai, Yokohama, Japan) and Cytovision software
(Leica Biosystems, Wetzlar, Germany).
For cell viability complementation assays, cells were treated with mitomycin C at the indi-
cated doses (between 50–500 nM) and incubated with drug for 96h following which cell viabil-
ity was measured by CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI).
Cell cycle complementation assay
Cell cycle analysis was performed on cells treated with vehicle (DMSO) or melphalan at the
indicated doses for 48h. Cells were then fixed with 70% ethanol. Following this, cells were
washed with PBS and then stained with PI/RNase Staining Buffer (BD Biosciences, San Jose,
CA, USA). Cell Cycle analysis was performed on the Beckton-Dickinson LSR Fortessa or BD
LSR II (BD, Franklin Lakes, NJ, USA).
Generation of isogenic BRCA2 haploinsufficient vs. wild-type T-ALL cells
We used Jurkat cells, which lack an identifiable BRCA2 mutation [39], to generate isogenic
clones with monoallelic BRCA2 mutations. We first generated a guide RNA targeting exon 11
of BRCA2 (NM_000059; guide RNA target sequence TACAACTTGTGTAAAAAGCTA) in
the guide RNA expression vector pHKO9-combomod-Puro [40]. This guide RNA was pack-
aged into an integration deficient lentivirus by transfection into 293T cells, together with the
integration-defective packaging plasmid psPAX2-D64V (https://www.addgene.org/63586/)
and the pMD2.G envelope plasmid (https://www.addgene.org/12259/).
Jurkat T-ALL cells were first transduced with a blasticin-resistant Cas9 expression lentivirus
(https://www.addgene.org/52962/), and selected with blasticidin for 10 days. Cells were then
transduced with the integration-defective BRCA2-targeting guide RNA by incubating cells for
24 hours in virus-containing supernatant in the presence of polybrene at 8 μg/mL, and then
subjected to selection with puromycin (2 μg/ml) for 24 hours, followed by single cell cloning
using serial dilution. The BRCA2 target locus of these single-cell clones were Sanger sequenced
using the following primers for PCR amplification: forward- 5-‘TGTGGTGCCACCTAAG
CTCT-3’ and reverse- 5’-TCTGGTTGACCATCAAATATTCC-3’ and the forward
primer was used for sequencing to identify those with monoallelic mutations predicted to
result in premature termination of translation.
RNA sequencing of isogenic BRCA2 haploinsufficient vs. wild-type T-ALL
cells
RNA was extracted from BRCA2 wild-type or heterozygous mutant clones using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA samples were then
treated with Ambion Turbo DNAse (Thermo Fisher Scientific, Waltham, MA), and DNA con-
tamination was confirmed to be<10% for all samples. RNA quantity was determined using
the Qubit RNA Assay Kit (Thermo Fisher Scientific) and RNA quality was determined on an
Agilent Bioanalyzer using the RNA Pico Kit (Agilent, Santa Clara, CA). Using the NEBNext
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Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA), 50–100 ng of
total RNA was converted into a DNA library following the manufacturer’s protocol. Following
library construction, DNA libraries were assessed for quality control. Library quantity was
determined using the Qubit High Sensitivity DNA Kit (Thermo Fisher Scientific) and library
size was determined using the Bioanalyzer High Sensitivity Chip Kit (Agilent). Finally, libraries
were put through qPCR using the Universal Library Quantification Kit for Illumina (Kapa Bio-
systems, Wilmington, MA) and run on the 7900HT Fast qPCR machine (Applied Biosystems,
Foster City, CA). Libraries passing quality control were diluted to 2 nM using sterile water and
then sequenced on the NextSeq500 (Illumina, San Diego, CA) at a final concentration of 2 pM
on a paired end flowcell with 75 sequencing cycles in each direction, following all manufac-
turer protocols. Alignments were performed with STAR aligner (version 2.3.1z4) against the
hg19 w ERCC92 genome (ftp://ftp.ensembl.org/pub/release-75/fasta/homo_sapiens/dna/).
Aligned files were processed to primary (raw) read counts using featureCounts, and primary
read counts were normalized using DESeq2. Gene set enrichment analysis was performed
using GenePattern (http://software.broadinstitute.org/cancer/software/genepattern). RNA-seq
data are available in NCBI GEO (https://www.ncbi.nlm.nih.gov/geo), accession number
GSE126780.
UV treatment in isogenic BRCA2 haploinsufficient vs. wild-type T-ALL
cells
BRCA2 haploinsufficient Jurkat T-ALL clones W4 and W5, together with parental BRCA2
wild-type cells transduced with Cas9 alone, were suspended in 100 μL and plated at 10 million
cells/ml in a 6-well plate. Cells were exposed to UV-C using the Stratalinker 2400 (Stratagene,
La Jolla, CA) at 30 J/m2 or no UV. Cells were then plated at 0.1 million cells/mL in a 96-well
plate, and cell viability was measured by CellTiter-Glo Cell Viability Assay after 96 hours.
In vitro drug treatment of isogenic BRCA2 haploinsufficient vs. wild-type
T-ALL cells
BRCA2 haploinsufficient Jurkat T-ALL cells or their Cas9-transduced BRCA2 wild-type con-
trols were plated at 0.1 million cells/ml in 96 well plates, and treated with vehicle (DMSO or
PBS) control and at the indicated concentrations of VE-821 (SelleckChem, S8007), Topotecan
(SelleckChem, S1231), KU60019 (SelleckChem, S1570), Mitomycin C (Sigma, M4287), PF-
477736 (SelleckChem, S2904), Olaparib (SelleckChem, S1060), CCT-241533 (Tocris, 4968),
Etoposide (Sigma, E1383), C527 (ApexBio, A8693), PHA-767491 (SelleckChem, S2742), MK-
1775 (SelleckChem, S1525) for 96 hours. Cell viability was measured by CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega, Madison, WI).
For 15-day treatment of BRCA2-haploinsufficient vs. wild-type controls, clone W4, clone
W5, and parental Cas9 control cells were plated at 0.1 million cells/ml and split every 4 days at
1:9 in growth media (RPMI1640 with 10% FBS) in the presence of vehicle or drug. Cells were
treated with VE821 (1 μM), AZD6738 (AstraZeneca, 0.25 μM), or vehicle (DMSO), and cell
viability was measured by CellTiter-Glo Luminescent Cell Viability Assay when cells were
split. Cell counts of drug-treated cells are normalized to those in vehicle-treated cells at that
time point.
Mice
NOD rag gamma (NRG) mice were purchased from Jackson Laboratory (Bar Harbor, ME;
strain #007799). 6 to 8-weeks old male NRG mice were used for experiments, and mice were
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randomly assigned to experimental groups. Mice were handled in accordance with Good Ani-
mal Practice as defined by the Office of Laboratory Animal Welfare, under approval from the
Boston Children’s Hospital Institutional Animal Care and Use Committee (protocol # 18-09-
3784R).
In vivo drug treatment of isogenic BRCA2 haploinsufficient vs. wild-type
T-ALL cells
For in vivo experiments, BRCA2 haploinsufficient and their wild-type Cas9-expressing
controls were transduced with either EGFP or dTomato expressing constructs. EGFP or dTo-
mato protein-coding sequences were amplified in an attB-flanked PCR product from
EX-EGFP-LV105 (Genecopoeia) or pUltra-Chili (https://www.addgene.org/48687/), respec-
tively, and then Gateway-cloned into pLenti CMV Puro DEST (https://www.addgene.org/
17452/). Lentivirus was generated as described above, and BRCA2 haploinsufficient clone W5
cells and parental Cas9 control cells were transduced with either pLenti CMV Puro DEST
EGFP or dTomato lentivirus, as indicated. EGFP or dTomato positive cells were sorted using a
Facsaria II (BD Biosciences). Sorting efficiency (>99.5%) was confirmed by FACS analysis
before starting experiments. Cells were then mixed at 1:1 ratio, and injected by tail vein injec-
tion (0.5 million cells/mouse) into NRG mice. Mice were treated with irradiation (450 cGy) 3
hours prior to transplantation. Four days post-injection, treatment began with either vehicle
(40% propylene glycol, 50% sterile water, and 10% DMSO) or AZD6738 (25 mg/kg) in this
same vehicle by oral gavage, twice daily, for 12 days. Mice were anesthetized by 2% isoflurane
(v/v) prior to oral gavage. Mice were monitored daily and supportive care (hydrogel, bacon-
bites, and 300 μl normal saline solution via subcutaneous injection) were administered daily
for the duration of the experiment. Mice were euthanized using carbon dioxide at day 18 after
leukemia injection, the bone marrow was isolated and dissociated through a 40 μM mesh filter,
and red blood cells were lysed using Red Blood Cell Lysis reagent (BD Biosciences). EGFP and
dTomato fluorescence were assessed by flow cytometry using the LSRFortessa cytometer (BD
Biosciences). Data were analyzed using FlowJo version 10.4.2.
Statistical analyses
Differences in categorical data were assessed via Fisher’s exact test. Differences in continuous
data were assessed via the Welch t-test with Bonferroni correction for multiple hypothesis test-
ing when variance was similar among the groups (standard deviations < 2-fold different), or
via analysis of variance (ANOVA) with Dunnett’s adjustment for multiple hypothesis testing
when variance was similar. Differences in event-free and overall survival were assessed by the
log-rank test, and time-to-event distributions were estimated via the Kaplan-Meier method.
Results
Fanconi-BRCA mutations in human T-ALL
To further unravel the genetic basis of T-ALL, we applied targeted exon sequencing and array
CGH analysis to T-ALL diagnostic specimens collected from a cohort of children treated on
contemporary clinical trials (S2 Table). Sequencing analysis revealed 10 missense or splice site
alterations of Fanconi genes in 23% (n = 9 of 40) of T-ALL cases analyzed in our primary
cohort (Figs 1A and 2B, S2 and S3 Tables). All mutations were present at variant allele frac-
tions of 0.38–0.54, consistent with heterozygous clonal mutations in the bulk tumor popula-
tion (S3 Table). All mutations were validated by Sanger sequencing (S1 Fig). To validate these
findings in an independent cohort, we subjected an additional cohort of 69 independent
Fanconi-BRCA mutations in T-ALL
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Fig 1. Fanconi-BRCA pathway mutations in childhood T-ALL. (A) Childhood T-ALL diagnostic specimens were analyzed by
targeted exon sequencing and array CGH. The percentage of cases with mutations or deletions in each of the Fanconi complexes is
shown on a simplified schema of the Fanconi pathway, which functions in the repair of DNA inter-strand crosslinks. (B) Mutations
identified by targeted exon sequencing are shown for each of the mutated Fanconi-BRCA pathway genes. Allele fraction of the
mutation is shown in parentheses. (C-D) Comparison of white blood cell (WBC) count (C) or patient age (D) at the time of T-ALL
diagnosis in cases with or without Fanconi gene alterations. Significance assessed by two-sided Wilcoxon rank-sum test. (E) Co-
occurrence of Fanconi gene mutations with additional T-ALL oncogenic lesions identified by sequencing and copy number analysis.
https://doi.org/10.1371/journal.pone.0221288.g001
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primary T-ALL patient samples to targeted sequencing analysis. This revealed Fanconi-BRCA
pathway mutations in 17% (n = 12 of 69) of these cases (S4 and S5 Tables), an incidence not
significantly different than that in our original cohort (P = 0.6).
Sequencing of remission specimens of samples in the 8 Fanconi-BRCA mutant cases in our
primary cohort in which induction chemotherapy successfully cleared the bone marrow of
Fig 2. Fanconi-BRCA mutations in T-ALL encode pathogenic alleles. A panel of cell lines deficient for BRCA2 (VU423), FANCD2
(PD20), FANCA (GM6914), FANCC (PD331) or FANCF (EUFA121.L) were transfected with pcDNA3 (BRCA2) or retrovirally
infected with PMMP expression constructs encoding the wild-type (WT) gene (FANCD2, FANCA, FANCC, FANCF), control
vector, or each of the indicated point mutant alleles identified in T-ALL patient samples. (A) Relative mRNA expression of the
transduced genes was assessed by Q-RT-PCR analysis. All units are % of β-actin control. (B) The indicated cells were treated with
mitomycin C (MMC; 20 ng/mL) for 48 hours, and radial chromosome formation was assessed by metaphase spread analysis. Radial
chromosome formation was assessed in a minimum of 25 metaphases from each of three independent biologic replicates for each
condition, and are plotted as mean +/- s.e.m. (C) Representative metaphase spread from the experiment shown in (B), with black
arrows denoting radial chromosomes. (D) Relative viability was assessed by CellTiterGlo in the indicated cells transduced with the
indicated constructs, following treatment with mitomycin C (MMC) at the following dosing: BRCA2 cells, 500 nM; FANCD2 cells,
100 nM; FANCA cells, 100 nM; FANCC cells, 500 nM; FANCF cells, 50 nM. (E) Cell cycle analysis was performed by PI staining in
each of the transduced cell lines following treatment with melphalan at 0.25 μg/ml (BRCA2, FANCD2, FANCA, FANCC) or 0.5 μg/
ml (FANCF) for 48 hours. The change in the percentage of cells in G2/M is shown relative to that in DMSO vehicle-treated cells. (F)
Representative histograms of DNA content (PI) for each of the FANCF transduced cells in (E) are shown. All bar charts represent
the mean +/- s.e.m. of three independent biologic replicates, with significance assessed by Welch t-test with Bonferroni adjustment
for multiple comparisons as appropriate. ���, P� 0.001; ��, P� 0.01; �, P� 0.05; n.s., P> 0.05.
https://doi.org/10.1371/journal.pone.0221288.g002
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leukemia revealed that 6 of these mutations were somatic, whereas 2 were present in the remis-
sion specimen (S1 Fig), suggesting a germline origin. In addition, array CGH analysis of our
primary T-ALL cohort revealed 8 deletions involving Fanconi genes as part of large multi-gene
chromosomal aberrations in 19% (n = 7 of 36) of cases with sufficient material for array CGH
analysis (Fig 1A, S2 Fig, S2 Table). Overall, 15 (38%) of the 40 T-ALLs in the primary T-ALL
cohort analyzed had Fanconi-BRCA gene alterations. These cases had a significantly increased
WBC count (Fig 1C), and tended to be younger at the time of T-ALL diagnosis (Fig 1D). Strik-
ingly, all 5 T-ALL cases diagnosed before 6 years of age had Fanconi-BRCA mutations (5/5 vs.
10/25 in older patients, P = 0.005 by Fisher’s exact test). There were no significant differences
in clinical responses between Fanconi-BRCA mutant vs. wild-type cases (S3 Fig). Fanconi
alterations frequently co-occurred with mutations of NOTCH1, CDKN2A and polycomb
repressive complex 2 genes (Fig 1E, S3 Table), genes with well-established roles in T-ALL path-
ogenesis [41, 42], but Fanconi-BRCA mutations were not significantly associated with specific
molecular subtypes of T-ALL. A comparison of variant allele fractions for these mutations
revealed that Fanconi-BRCA mutations were most likely clonal (S2 and S3 Tables).
Fanconi-BRCA mutations identified in T-ALL encode pathogenic alleles
To test whether the identified Fanconi-BRCA mutations are pathogenic, we leveraged comple-
mentation analysis in a panel of cell lines with biallelic loss-of-function mutations in BRCA2,
FANCD2, FANCA, FANCC or FANCF [43, 44]. We note that none of the mutations we identi-
fied are known to be pathogenic, and most have not been previously reported in Fanconi or
BRCA mutation databases (S2 Table). Fanconi-deficient cells were transduced with expression
constructs encoding point mutant alleles identified, the respective wild-type gene, or a negative
control. The wild-type and mutant constructs were expressed at similar levels based on
Q-RT-PCR and Western blot analysis (Fig 2A and S5 Fig). Transduced cells were treated with
the DNA cross-linking agent mitomycin C, and radial chromosome formation was assessed by
metaphase spread analysis. This revealed that most of the Fanconi-BRCA mutant alleles tested
were impaired in their ability to rescue radial chromosome formation when compared to the
wild-type gene (Fig 2B and 2C). For example, the FANCD2 Q413E allele was indistinguishable
from a negative control, whereas FANCC S264R was approximately 75% as efficient as wild-
type at reducing radial chromosome formation. All mutant alleles except FANCA P259A were
also impaired in their ability to rescue Fanconi-deficient cells from the cytotoxicity of mitomy-
cin C (Fig 2D). We then tested whether these mutant alleles were impaired in their ability to
rescue G2/M arrest in response to melphalan, an alternative assay for canonical Fanconi path-
way function [45], and found that most of the mutant alleles tested were inferior to their corre-
sponding wild-type genes in this assay as well (Fig 2E and 2F). Thus, while some alleles are
only modestly impaired, these data indicate that Fanconi-BRCA mutations identified in child-
hood T-ALL encode hypomorphic or null alleles.
Inactivating the tumor suppressor activity of the Fanconi-BRCA pathway is generally
thought to require biallelic gene mutations, and biallelic gene mutations are detectable in 90%
of BRCA-mutant breast cancers [9]. However, there were no biallelic Fanconi-BRCA gene
mutations identified in any T-ALL sample in our cohort (S2 Table). Moreover, Sanger
sequencing from mRNA of Fanconi-mutant T-ALLs suggested that 8 of the 9 Fanconi-mutant
cases retained mRNA expression of the wild-type allele (Fig 3A, S1 Fig). To test whether the
wild-type allele is functional, we took advantage of the fact that cells with biallelic, but not
monoallelic, Fanconi-BRCA pathway mutations have gross defects in the repair of DNA cross-
links, detectable as hypersensitivity to inter-chromosomal fusions (radial chromosomes) in
response to DNA cross-linking agents [46], and are hypersensitive to the cytotoxicity of PARP
Fanconi-BRCA mutations in T-ALL
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inhibitors [27, 47, 48]. Treatment of T-ALL patient-derived xenograft (PDX) cells harboring a
heterozygous truncating BRCA2 p.Y1710X mutation (Fig 3A) revealed that these cells lacked
hypersensitivity to mitomycin C-induced radial chromosome formation (Fig 3B). These cells
also harbored no hypersensitivity to the PARP inhibitor olaparib, at doses that were highly
toxic to BRCA2-null VU423 cells (Fig 3C). While we lacked additional viable Fanconi-BRCA
mutant T-ALL cells to confirm that these findings are generalizable to T-ALLs with upstream
Fanconi gene mutations, these data suggest that T-ALLs are under little selective pressure to
completely inactivate the wild-type allele.
Fig 3. T-ALLs with monoallelic Fanconi-BRCA mutations retain expression of the wild-type allele. (A) Sanger sequencing of the mutant locus
was performed on T-ALL diagnostic genomic DNA (gDNA), T-ALL mRNA, or remission gDNA collected from the indicated patients. Arrows
denote the position of the mutation identified in T-ALL gDNA by next-generation sequencing. Sequencing from additional cases is shown in S1 Fig.
(B) Cells from T-ALL PDX D115 harboring a heterozygous BRCA2 p.Y1710X truncating mutation, control Fanconi wild-type lymphocytes, or
VU423 cells harboring biallelic BRCA2 inactivation were treated with vehicle or 20 ng/ml of MMC for 48h, and radial chromosome formation was
assessed by metaphase spread analysis. A minimum of 50 metaphase spreads per case were assessed. (C) The indicated cells were treated with the
PARP inhibitor olaparib at the indicated doses for 5 days, and viability was assessed using CellTiter Glo. Each experiment shows the mean +/- s.e.m.
of three biologic replicates. Significance was assessed at 1000 nM olaparib using a Welch t test with Bonferroni adjustment for multiple comparisons.
https://doi.org/10.1371/journal.pone.0221288.g003
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BRCA2 haploinsufficient T-ALL cells are hypersensitive to ultraviolet
irradiation and ATR inhibition
We then turned our attention to the cellular consequences of BRCA2 haploinsufficiency in
T-ALL, because this was the single most commonly mutated Fanconi-BRCA gene in this
cohort (Fig 1B). We first generated isogenic BRCA2 wild-type versus haploinsufficient T-ALL
cells in the human cell line Jurkat. We selected Jurkat cells because sequencing has identified
no pathogenic mutations in BRCA2 or other Fanconi-BRCA pathway genes [39]. Cas9-expres-
sing Jurkat cells were transiently transduced with an integration-defective lentivirus encoding
a guide RNA targeting exon 11 (the exon mutated in T-ALL PDX D115), and single-cell clon-
ing revealed two independent clones with monoallelic mutations predicted to result in prema-
ture termination of translation (Fig 4A and 4B). There was no significant difference in relative
viability of BRCA2 haploinsufficient versus parental clones (S6 Fig).
We began by performing RNA-seq analysis on these two BRCA2-haploinsufficient Jurkat
clones, together with two BRCA2 wild-type control clones (Cas9-expressing and untransduced
parental Jurkat cells). Gene set enrichment analysis revealed that BRCA2 haploinsufficiency
was associated with increased expression of the Hallmark_DNA_Repair gene set (Fig 4C), rep-
resenting genes whose coordinate expression is associated with DNA damage repair in a broad
spectrum of experimental conditions [49]. BRCA2 haploinsufficient cells were also character-
ized by increased expression of genes upregulated in response to ultraviolet (UV) irradiation,
and decreased expression of genes downregulated in the UV response (Fig 4D), suggesting
that BRCA2 haploinsufficient cells might have limited reserves to tolerate UV irradiation. UV
radiation induces pyrimidine dimers that are typically repaired by nucleotide excision repair
or trans-lesion synthesis [50]. However, UV radiation during S phase does trigger activation of
the Fanconi-BRCA pathway [51], and FANCD2 function is required for genomic integrity fol-
lowing UV-induced replication stress [52]. We found that BRCA2-haploinsufficient cells were
Fig 4. BRCA2 haploinsufficiency induces sensitivity to ultraviolet irradiation. (A-B) Cas9-expressing Jurkat T-ALL cells were
transiently transduced with a guide RNA targeting the locus indicated in (A). Cells were single cell cloned, and Sanger sequencing
identified the two clones with monoallelic frameshift mutations shown in (B). (C) RNA-seq was performed on the two BRCA2
haploinsufficient clones, together with parental or Cas9-transduced Jurkat controls, and gene set enrichment analysis was
performed. NES, normalized enrichment score. (D) An equal number of the indicated cells were subjected to 30 J/m2 ultraviolet
irradiation, and viability was assessed at 96 hours. (E) Viability was normalized to that in non-irradiated controls. Significance was
assessed by Welch t test.
https://doi.org/10.1371/journal.pone.0221288.g004
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selectively sensitized to UV irradiation at doses that had minimal toxicity to their isogenic
wild-type counterparts (Fig 4E).
We then asked whether therapeutic vulnerabilities induced by BRCA2 haploinsufficiency
could be exploited using drugs. We screened a panel of small molecules selected based on their
potential to trigger DNA replication-dependent toxicity, in BRCA2 haploinsufficient clone W5
cells versus their isogenic wild-type counterparts (S7 Fig). This revealed that the ATR inhibitor
VE-821 [53] was selectively toxic to cells harboring monoallelic BRCA2 mutations following 4
days of treatment (Fig 5A). To confirm these findings, we then treated our two independent
BRCA2 haploinsufficient clones with either VE-821 or the structurally distinct ATR inhibitor
AZD6738 [54], and found that ATR inhibition exhibits sustained differential toxicity to
BRCA2 haploinsufficient Jurkat T-ALL cells (Fig 5B and 5C). While T-ALL patient-derived
xenografts are unable to be maintained in cell culture for more than a few days, short-term
treatment of a panel of T-ALL PDX cells revealed that the ATR inhibitor AZD6738 was toxic
only to those from a case harboring a monoallelic BRCA2 truncating mutation (Fig 5D).
To test the in vivo therapeutic potential of ATR inhibition in BRCA2 haploinsufficient
T-ALL, we first transduced BRCA2-haploinsufficient clone W5 cells with EGFP, and their iso-
genic parental cells with dTomato. These cells were mixed in a 1:1 ratio, and injected into a
cohort of immunodeficient mice. Four days after injection, mice were treated either with vehi-
cle or the ATR inhibitor AZD6738 via gavage for 12 days, and relative fitness of BRCA2 mutant
versus wild-type clones was assessed by flow cytometry analysis of the bone marrow. This
experimental design ensures that both clones are treated under identical conditions. BRCA2
haploinsufficient versus wild-type clones had indistinguishable growth characteristics in vehi-
cle-treated mice. However, we found that the ATR inhibitor AZD6738 was selectively toxic to
T-ALL cells harboring a monoallelic BRCA2 mutation (Fig 5F and 5G). To rule out the possi-
bility that this result reflected differential toxicity of the EGFP versus dTomato fluorescent pro-
teins, we repeated this experiment with the labels swapped, which revealed nearly identical
results (Fig 5H and 5I). Thus, BRCA2 haploinsufficiency selectively sensitizes T-ALLs to ATR
inhibition.
Discussion
The identification of a high frequency of pathogenic Fanconi-BRCA mutations implicates this
pathway in the molecular pathogenesis of human T-ALL, a possibility first raised by the spon-
taneous development of thymic lymphomas in Brca2-deficient mice [17, 18]. While T-cell
transformation can occur with biallelic Fanconi-BRCA pathway mutations [17–19], the fact
that all mutations in human T-ALL appeared to be monoallelic suggests that partially
impaired, rather than absent, Fanconi pathway activity may provide optimal fitness during T-
cell transformation. This model posits that Fanconi-BRCA haploinsufficiency sufficiently
impairs some functions of the pathway to collaborate with other oncogenic lesions during T-
cell transformation. Haploinsufficiency for some downstream Fanconi-BRCA genes has previ-
ously been shown to induce replication stress and impair DNA repair [55, 56], and we found
that BRCA2 haploinsufficiency induced gene expression alterations suggesting activation of a
DNA damage response, as well as hypersensitivity to UV radiation. However, the lack of selec-
tion for loss of the wild-type allele suggests that retaining some Fanconi pathway function is
beneficial, presumably by suppressing the deleterious consequences of extensive genomic
instability. The relative specificity of this observation to the T-cell lineage may reflect the
hypersensitivity of normal T-cell progenitors to DNA damage-induced apoptosis [57]. How-
ever, this is not unique to the T-cell lineage, as BRCA2 can function as a haploinsufficient
tumor suppressor during pancreatic transformation [58].
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Fig 5. BRCA2 haploinsufficiency induces hypersensitivity to ATR inhibition. (A) Jurkat BRCA2-haploinsufficient clone W5 cells, and
Cas9-transduced parental controls, were treated with the indicated drugs for 96 hours, and viability was assessed using CellTiter Glo. Graph
denotes the mean +/- s.e.m. of the fold change in IC50 between BRCA2 +/- versus parental cells from triplicate experiments. Significance
assessed by repeated measures two-way ANOVA. (B-C) The indicated BRCA2 haploinsufficient Jurkat clones, or Cas9-transduced parental
controls, were treated with the ATR inhbitors VE-821 (1 μM) or AZD6738 (0.25 μM), and cell viability was assessed by CellTiter Glo at the
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It is worth noting that a recent whole-exome sequencing (WES) study of a large T-ALL
cohort detected a significantly lower rate of Fanconi-BRCA mutations than that reported in
our study [59]. We confirmed each of the mutations identified in our cohort by Sanger
sequencing, which rules out the possibility of next-generation sequencing artifacts, and also
validated our findings in an independent cohort. We believe this apparent discrepancy reflects
the difficulty of distinguishing pathogenic mutations from non-pathogenic passengers by
informatics alone. The authors of this recent WES study applied a strict algorithm for muta-
tion calling, which required mutations to be previously known to be pathogenic or clearly pre-
dicted to disrupt protein structure [59]. This is entirely appropriate, because without this the
list of mutations identified in genome-wide cancer sequencing studies would be dominated by
non-pathogenic variants, which are much more common. However, an unavoidable conse-
quence of this approach is a bias against calling mutations not previously known to be patho-
genic. We note that most of the pathogenic Fanconi-BRCA mutations we identified were
missense substitutions not previously known to be pathogenic, and their functional
impairment was not well correlated with predicted pathogenicity by a range of existing infor-
matics tools, in line with prior reports [60, 61]. We note that recent efforts using novel infor-
matics algorithms designed to better predict pathogenic mutations have also revealed Fanconi-
BRCA mutations in other tumor types in which these had not previously been recognized by
large-scale sequencing efforts [62–64]. These findings highlight the complementary strengths
of human cancer genomics and functional genetics to decipher the molecular pathogenesis of
human cancer.
We found that haploinsufficiency for BRCA2, the most commonly mutated Fanconi gene
in our cohort, induced a gene expression signature suggesting activation of a DNA damage
response, and BRCA2 haploinsufficient cells were hypersensitive to UV radiation at doses that
lacked detectable toxicity to their wild-type counterparts. These cells were also selectively sen-
sitized to ATR inhibition, but not to drugs such as PARP inhibitors that are toxic only in the
setting of biallelic (and not monoallelic) Fanconi-BRCA inactivating mutations [27, 47, 48].
Our data provide a rationale for the application of ATR inhibitors in T-ALLs with somatic
BRCA gene mutations, and suggest the need to test this strategy in other tumors with monoal-
lelic Fanconi-BRCA gene mutations. ATR inhibitors are currently in clinical trials for a broad
spectrum of tumor types, and it will be of considerable interest to assess whether Fanconi-
BRCA mutations provide a biomarker of response to ATR inhibition across human cancer
subtypes.
Supporting information
S1 Fig. Confirmation of Fanconi-BRCA point mutations identified in childhood T-ALL by
Sanger sequencing. Sanger sequencing was performed to confirm all Fanconi-BRCA point
mutations identified in primary T-ALL patient samples in genomic DNA (left). Two additional
cases are shown in Fig 3a. Sequencing of cDNA (middle) revealed that all samples but one
indicated time points. Graphs denotes the mean +/- s.e.m. of biologic triplicates. (D) T-ALL patient-derived xenograft (PDX) cells were
treated for 4 days with AZD6738 (0.8 mM), and viability was assessed by CellTiter Glo. Graph denotes the mean +/- s.e.m. of biologic
triplicates. Significance assessed by one-way ANOVA with Dunnett’s correction for multiple hypothesis testing. (E) Schema of experimental
design. Vehicle or 25 mg/kg/dose AZD6738 were administered by gavage every 12 hr. (F) Mice were injected with a 1:1 mix of dTomato-
labeled BRCA2 haploinsufficient clone W5 and EGFP-transduced parental Cas9 (BRCA2 wild-type) cells, and treated as shown in (E).
Abundance of each fluorescently labeled clone in the bone marrow was assessed by flow cytometry on day 18. Significance was assessed by
two-sided Welch t-test. (G) Representative flow cytometry plots from the experiment shown in (E). (H-I) Mice were injected, treated and
analyzed as in (F-G), with the fluorescent labels swapped: BRCA2 haploinsufficient cells were transduced with EGFP, and parental Cas9
(BRCA2 wild-type) cells were transduced with dTomato. ���, P� 0.001; ��, P� 0.01; �, P� 0.05; n.s., P> 0.05.
https://doi.org/10.1371/journal.pone.0221288.g005
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(T-ALL C03) retained expression of the wild-type allele at the mRNA level. Sequencing of
remission bone marrow or peripheral blood specimens in all cases that achieved a remission
revealed that 6 of 8 mutations were somatic, whereas 2 mutations were present in the remis-
sion specimen. We lacked a non-hematopoietic germline sample to distinguish whether these
mutations were germline or indicative of clonal hematopoiesis.
(PDF)
S2 Fig. Fanconi deletions in childhood T-ALL. (A-D) Array CGH was performed on all
T-ALL diagnostic specimens with sufficient material available, which revealed large heterozy-
gous deletions involving FANCG (A), FANCC (B), SLX4 (C) and FANCA (D) in 8 (22%) of
these 36 cases. The chromosome segment shown is indicated in the ideogram (left). Segmented
array CGH copy number data is shown on the right, with each column representing an indi-
vidual T-ALL patient sample. Color indicates the log2 copy number ratio, as indicated in the
legend (bottom left).
(PDF)
S3 Fig. Fanconi mutations are not associated with T-ALL treatment response. (A-B)
Kaplan-Meier survival analysis of the 40 children with T-ALL in the primary cohort of cases in
this study, from patients treated on clinical trials COG AALL0434 or DFCI 05001, comparing
cases with a Fanconi gene mutation or deletion versus those without a Fanconi mutation iden-
tified (Fanconi wild-type). P values were calculated using the log-rank test. (C-D) Kaplan-
Meier survival analysis from an independent validation cohort of 69 children with T-ALL
treated on DFCI 05001. P values were calculated by log-rank test.
(PDF)
S4 Fig. Western blot analysis of Fanconi-BRCA deficient cells transduced with wild-type
or mutant expression constructs for complementation experiments shown in Fig 2. (A)
FANCA-deficient cells GM6914 were transduced with empty vector, FANCA WT (WT) or
FANCA P259A (P259A). (B) FANCC-deficient PD331 cells were transduced with empty
vector, FANCC WT or FANCC S264R (S264R). (C) FANCF-deficient EUFA121 cells were
transduced with empty vector (EV), FANCF WT (WT) or FANCF P117T (P117T). (D)
FANCD2-deficient PD20 cells were transduced with empty vector (vector), FANCD2 WT
(WT) or FANCD2 Q413E (Q413E). (E) BRCA2-deficient VU423 cells were transduced with
Luciferase (Luc), BRCA2 WT (WT), BRCA2 Y2543C (Y2543C), BRCA2 R324T (R324T), and
BRCA2 M927V (M927V) mutations. U2OS cells are shown as a positive control for BRCA2
expression.
(PDF)
S5 Fig. The D115 T-ALL patient-derived xenograft harbors a BRCA2 heterozygous muta-
tion. Sanger sequencing analysis of genomic DNA revealed the presence of a heterozygous
BRCA2 mutation resulting in premature termination of translation in this patient-derived
xenograft.
(PDF)
S6 Fig. Baseline viability of BRCA2 haploinsufficient vs. parental Cas9 isogenic clones. An
equal number of cells were seeded at day 0, and cell growth was assessed at the indicated time
points by CellTiter Glo analysis. Viability is shown relative to day 0.
(PDF)
S7 Fig. Viability curves of BRCA2 haploinsufficient vs. parental Cas9 isogenic clones upon
treatment with the drugs shown in Fig 5A. Cells were treated with the indicated drugs and
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doses, and cell viability was assessed by CellTiter Glo at 96 hours. Viability is normalized to
that in vehicle-treated control for each cell type.
(PDF)
S1 Table. Genes sequenced by targeted exon sequencing.
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S2 Table. Primary T-All patient samples analyzed in Primary Patient Cohort.
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S3 Table. Results of targeted exon sequencing in Primary Patient Cohort.
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S5 Table. Results of targeted exon sequencing in Validation Patient Cohort.
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S6 Table. Primers used for PCR amplification, Sanger sequencing, site-directed mutagene-
sis, and quantitative PCR.
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